A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma
This study is for people who have a high-risk form of smouldering multiple myeloma. This is a precancerous condition where abnormal cells are found in the bone marrow but haven't yet caused serious problems, like advanced multiple myeloma. The study wants to find out if a new medicine, called daratumumab (JNJ-54767414), given by injection under the skin, can prevent or delay this condition from developing into full-blown multiple myeloma. Researchers will compare those who receive the drug with those who are carefully watched, to see which group has a longer time before the condition progresses. This is a Phase 3 study, meaning it’s a later stage of research designed to confirm if the new treatment is safe and effective.
At a glance
What is this study about?
This clinical trial is designed to investigate a condition called 'high-risk smouldering multiple myeloma'. This is a type of blood condition where abnormal cells, called plasma cells, build up in your bone marrow. While it's not full-blown cancer, it has a higher chance of developing into a more serious form of blood cancer called multiple myeloma over time. The goal of this study is to see if a particular medicine, called daratumumab (you might see it referred to by its study code, JNJ-54767414), can help prevent or delay this progression. It's a 'Phase 3' study, which means it’s a large, important step in testing a new treatment, comparing it against the usual care to see if it's better.
The study treatment, daratumumab, is given as an injection just under the skin. Half of the participants will receive this medicine as part of the study, while the other half will receive 'active monitoring'. Active monitoring means they will be closely watched by doctors through regular check-ups and tests, which is a common approach for smouldering multiple myeloma today. This comparison helps researchers understand if the new drug offers a real benefit over current practice.
The main thing the researchers want to find out is how long people in each group go without their smouldering multiple myeloma getting worse or turning into multiple myeloma. This is called 'progression-free survival'. They will also look at how long people live overall, and monitor any side effects of the medication. This research is really important because it could lead to new ways to prevent multiple myeloma for people living with the high-risk smouldering form.
Key takeaways
- This study aims to see if a new drug can stop a precancerous blood condition from getting worse.
- It's for people with 'high-risk smouldering multiple myeloma'.
- The new drug, daratumumab, is given by injection under the skin.
- Participants will either get the drug or be closely watched (active monitoring).
- The study compares which approach leads to a longer time without the condition progressing.
- Regular clinic visits and tests will be part of the study for several years.
Who may be eligible?
To be considered for this study, you need to be an adult, aged 18 or older. There is no upper age limit, so older adults can also take part. The study is open to both men and women.
The most specific requirement is that you must have a diagnosis of 'high-risk smouldering multiple myeloma'. This means you have a particular stage of this blood condition that doctors believe is more likely to progress to full multiple myeloma. Your doctor will be able to confirm whether your specific condition fits the criteria for 'high-risk'.
There will also be other medical requirements and tests to ensure that taking part in the study would be safe for you. These might include blood tests, checks on your overall health, and making sure you don't have certain other medical conditions. Your study doctor will go through all of these in detail with you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with 'high-risk smouldering multiple myeloma'?
- Are you able to attend regular clinic appointments and undergo medical tests?
- Are you seeking new ways to manage your high-risk smouldering multiple myeloma?
What does participation involve?
If you decide to join this study, you will be randomly assigned to one of two groups, like flipping a coin. One group will receive the study medicine, daratumumab, given as an injection under the skin. The other group will undergo 'active monitoring', meaning you'll have regular medical check-ups and tests, consistent with how this condition is often managed. You won't get to choose which group you are in; this is done to make the study fair and scientific.
The study involves regular visits to the clinic for treatments, check-ups, and tests like blood tests, and possibly bone marrow biopsies, to carefully monitor your condition and health. These visits will happen at set times over a period of many months, potentially years, to track your progress and any changes in your health. There will also be a follow-up period after your main treatment or monitoring phase ends to continue observing your long-term health.
The total duration of your participation could be several years, combining the active treatment/monitoring phase and the follow-up period. The medical team will explain the full schedule of visits, tests, and medication administration (if applicable) during the informed consent process.
Potential risks and benefits
Locations (13)
- —UnverifiedDenmark
- —UnverifiedSweden
- —UnverifiedCzechia
- —UnverifiedBelgium
- —UnverifiedHungary
- —UnverifiedSpain
- —UnverifiedNetherlands
- —UnverifiedFrance
- —UnverifiedNorway
- —UnverifiedItaly
- —UnverifiedGermany
- —UnverifiedPoland
Common questions
What is 'smouldering multiple myeloma'?
It's a precancerous condition where abnormal cells are found in your bone marrow, but they haven't yet caused serious health problems or symptoms of full multiple myeloma.
What is daratumumab and how is it given?
Daratumumab is a study drug (JNJ-54767414) that aims to prevent the condition from getting worse. It is given as an injection just under the skin.
What does 'active monitoring' mean in this study?
Active monitoring means that if you're in this group, doctors will closely watch your condition through regular check-ups and tests, but you won't receive the study drug.
How long will I be in the study?
Your participation could last for several years, including periods of treatment or monitoring and a follow-up to track your long-term health.
Can I choose which treatment group I'm in?
No, you will be randomly assigned to either the study drug group or the active monitoring group to ensure the study is fair and scientific.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.